Shanghai MicuRx Pharmaceutical (SHA:688373) completed the third phase of the clinical trial of oral cantizolid tablets, or MRX-4, in China.
Study results showed that MRX-4 is effective in treating complex skin and soft tissue infections, with the tablets showing good patient safety and tolerability, according to a Thursday filing with the Shanghai bourse.
Meanwhile, the international third phase trial of the medication for treating diabetic foot infection is ongoing.
Shares of the drugmaker were down 1% Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。